Skip to content

Effect of allopurinol on diabetic nephropathy

Evaluation of the effect of allopurinol on nephropathy in diabetic patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200117046158N1
Enrollment
60
Registered
2020-03-14
Start date
2020-02-14
Completion date
Unknown
Last updated
2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy. Drug or chemical induced diabetes mellitus with diabetic nephropathy

Interventions

Intervention 1: Intervention group: Patients in the case group are treated with allopurinol 100 mg daily. Intervention 2: Control group: Patients in the control group receive one placebo daily.

Sponsors

Shahre-kord University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 24-hour urine protein greater than 150mg / dl Uric acid between 6 and 15 Informed patient satisfaction The severity of diabetic nephropathy is similar in both groups Passive urine sedimentation

Exclusion criteria

Exclusion criteria: Patients treated with allopurinol Patients with significant renal failure (Cr> 3 mg / dl) or (GFR <25cc / min)

Design outcomes

Primary

MeasureTime frame
Serum uric acid level. Timepoint: After 3 and 6 months after starting the study. Method of measurement: Test.;GFR (Glomerular filtration rate). Timepoint: After 3 and 6 months after starting the study. Method of measurement: Formula.;24-hour urine protein content. Timepoint: After 3 and 6 months after starting the study. Method of measurement: 24-hour urine test.;Serum creatinine level. Timepoint: After 3 and 6 months after starting the study. Method of measurement: Test.;Serum urea level. Timepoint: After 3 and 6 months after starting the study. Method of measurement: Test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Mardani

Shahre-kord University of Medical Sciences

drsmardani@yahoo.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026